Concepedia

Complement Inhibitor Development

Complement Inhibitor Development is a pharmacological research endeavor that involves the design and optimization of therapeutic agents specifically targeting and modulating components of the complement system to prevent or treat complement-mediated diseases.

129

Publications

7.2K

Citations

820

Authors

284

Institutions

Publications per year

2017–2026

35

Parents

Publications

129

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Russell P. Rother, Scott A. Rollins, Christopher F. Mojcik et al. · Nature Biotechnology · 2007 · 764 citations

, , +13

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study

Samantha C. Gouw, Johanna G. van der Bom, H. Marijke van den Berg · Blood · 2007 · 487 citations

, , +14

Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor

Suzan H. M. Rooijakkers, Jin Wu, Maartje Ruyken et al. · Nature Immunology · 2009 · 220 citations · Full text

, , +13

Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria

Antonio M. Risitano, Daniel Ricklin, Yijun Huang et al. · Blood · 2014 · 195 citations · Full text

, , +11

Isolation of human S-protein, an inhibitor of the membrane attack complex of complement.

Eckhard R. Podack, Hans J. Müller‐Eberhard · Journal of Biological Chemistry · 1979 · 179 citations · Full text

, , +6

1–5 of 129

Authors

820

  1. JD
    John D. Lambris

    University of Pennsylvania, United States

    14 publications · 1.1K citations

    13

    h-index

  2. DR
    Daniel Ricklin

    University of Pennsylvania, United States

    9 publications · 911 citations

    9

    h-index

  3. DM
    Dimitrios Morikis

    University of California, Riverside, United States

    6 publications · 193 citations

    6

    h-index

  4. BP
    B. Paul Morgan

    Cardiff University, United Kingdom

    6 publications · 189 citations

    6

    h-index

  5. VM
    V. Michael Holers

    University of Colorado Denver, United States

    6 publications · 476 citations

    6

    h-index

1–5 of 820

Institutions

284

  1. University of Pennsylvania

    Philadelphia, United States

    15 h-index

    52 publications

    4.7K citations

  2. Cardiff University

    Cardiff, United Kingdom

    7 h-index

    18 publications

    514 citations

  3. University of Colorado Denver

    Denver, United States

    6 h-index

    10 publications

    582 citations

  4. Alexion Pharmaceuticals (United States)

    Boston, United States

    6 h-index

    24 publications

    4.1K citations

  5. University Medical Center Utrecht

    Utrecht, The Netherlands

    6 h-index

    27 publications

    2.9K citations

  6. Leiden University Medical Center

    Leiden, The Netherlands

    6 h-index

    11 publications

    1K citations

  7. Novartis (Switzerland)

    Basel, Switzerland

    5 h-index

    64 publications

    3.4K citations

  8. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

    5 h-index

    10 publications

    462 citations

1–8 of 284

Venues

  1. Blood

    13 publications · 1.4K citations

    12

    h-index

  2. The Journal of Immunology

    JI · 9 publications · 475 citations

    9

    h-index

  3. Journal of Medicinal Chemistry

    9 publications · 389 citations

    9

    h-index

  4. Molecular Immunology

    9 publications · 417 citations

    9

    h-index

  5. Bioorganic & Medicinal Chemistry Letters

    8 publications · 174 citations

    8

    h-index

1–5